Merrimack jumps 8.6% pre-market on Actavis production partnership

Merrimack Pharmaceuticals (MACK) shares jump 8.6% pre-market after the company enters a 10-year development, license, and supply agreement with Actavis which will use Merrimack's nanoliposomal tech platform to develop products for Actavis.

The first product Merrimack will produce is the bulk form of doxorubicin HCI liposome injection; Actavis will process the finished product and commercialize it globally.

Merrimack is eligible to receive up to $15.5M under the agreement, $2M upfront with the remaining payments coming at certain milestones. Merrimack will also receive a "double digit share" of the net profits. (8-K)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs